COVID-19 convalescent plasma: current status,lessons from the past and future perspectives |
| |
Institution: | 1. Laboratory for Immunology and Transfusion Medicine, Haugesund Hospital, Norway;2. Norwegian Directorate of Health, Oslo, Norway;3. Department of Immunology , Oslo University Hospital, Norway |
| |
Abstract: | When the COVID-19 pandemic hit, blood transfusion services worldwide started collection of convalescent plasma as early as possible, as exemplified by the response in Norway. There were challenges related to donor selection, donor safety, testing for relevant antibodies and indications for and dosing of the convalescent plasma. As more knowledge became available, the product quality was more standardised. Multiple case reports, observational studies and some randomized studies were published during the pandemic, as well as laboratory studies reporting different approaches to antibody testing. The results were conflicting and the importance of convalescent plasma was disputed.Even though there has been strong international collaboration with involvement of many key organisations, we may better prepare for the next pandemic. An even stronger, more formalised collaboration between these organisations could provide more clear evidence of the importance of convalescent plasma, based on the principles of passive immunisation. |
| |
Keywords: | COVID-19 convalescent plasma International collaboration Randomised clinical trials |
本文献已被 ScienceDirect 等数据库收录! |
|